


Summary

Name	CD30/TNFRSF8/CD30L Receptor/Tumor necrosis factor receptor superfamily member 8/Ki-1 antigen/Lymphocyte activation antigen CD30
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/ μ g as determined by LAL test.
Construction	Recombinant Human Tumor necrosis factor receptor superfamily member 8 is produced by our Mammalian expression system and the target gene encoding Phe19-Lys379 is expressed with a mouse IgG1 Fc tag at the C-terminus.
Accession #	P28908
Host	Human Cells
Species	Human
Predicted Molecular Mass	64.8 KDa
Formulation	Lyophilized from a 0.2 μ m filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 μ g/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Product Name: Recombinant Human CD30 (C-mFc)
Catalog #: PHH2315



Background

Alternative Names

Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30; CD30; TNFRSF8

Background

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family, which regulates proliferation/apoptosis and antibody responses. CD30 is expressed by activated, but not by resting, T and B cells. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. CD30 has been considered as a specific diagnostic biomarker of anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (cHL). CD30 is also a biomarker used for targeted therapy by an antibody–drug conjugate.

Note

For Research Use Only , Not for Diagnostic Use.